本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Disc Medicine

59.98
-0.9100-1.49%
盤後59.980.00000.00%16:10 EDT
成交量:55.17萬
成交額:3,316.19萬
市值:22.89億
市盈率:-9.98
高:61.66
開:60.26
低:59.11
收:60.89
52周最高:99.50
52周最低:30.82
股本:3,816.01萬
流通股本:3,288.51萬
量比:1.36
換手率:1.68%
股息:- -
股息率:- -
每股收益(TTM):-6.0116
每股收益(LYR):-6.0116
淨資產收益率:-35.86%
總資產收益率:-22.55%
市淨率:3.09
市盈率(LYR):-9.98

資料載入中...

公司資料

公司名字:
Disc Medicine
交易所:
NASDAQ
成立時間:
2017
員工人數:
155
公司地址:
321 Arsenal Street,Suite 101,Watertown,Massachusetts,United States
郵編:
02472
電話:
傳真:
- -
簡介:
Disc Medicine,Inc.於2020年6月25日作為特拉華州公司註冊成立。該公司是一家臨床階段的生物製藥公司,專註於為嚴重血液疾病開發新型療法。其研發管線針對紅細胞生成和功能中的基本生物學通路,主要候選藥物bitopertin正被開發用於治療紅細胞生成性卟啉症,其他候選藥物則針對貧血及相關疾病。

董事

名稱
職位
Donald W. Nicholson
Executive Chairman of the Board
John D. Quisel
Director, President and Chief Executive Officer
Georges Gemayel
Independent Director
Kevin Bitterman
Independent Director
Liam Ratcliffe
Independent Director
Mark Chin
Independent Director
William R. White
Independent Director
Nadim Ahmed
Director

股東

名稱
職位
John D. Quisel
Director, President and Chief Executive Officer
Jonathan Yu
Chief Operating Officer
Jean M. Franchi
Principal Accounting Officer, Chief Financial Officer and Treasurer
Donald W. Nicholson
Executive Chairman of the Board
Pamela Stephenson
Chief Commercial Officer
Rahul Khara
Chief Legal Officer
William Savage
Chief Medical Officer